Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Williams Companies Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B), while Williams Companies Inc trades at $72.72 (market cap $89.05B). The key difference: Williams Companies Inc is far larger — about 12.1× Spyre Therapeutics Inc. Common Stock's market cap, and Williams Companies Inc pays a 2.88% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Williams Companies Inc for 58 Days on average.
| SYRE | WMB | |
|---|---|---|
Market Cap | $7.35B | $89.05B |
Volume | 1,624,631 | 10,633,946 |
Sector | Health | Energy |
52-Week High | $108.92 | $79.40 |
52-Week Low | $22.18 | $56.51 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $6.35B | $119.67B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Williams Companies (WMB) trades at $74.57, up 0.54% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while technical indicators signal bullish momentum with support at $72-73 and resistance at $75-76. The company benefits from stable fee-based revenues and strategic positioning in natural gas infrastructure.
WMB presents a compelling investment case with strong cash flow generation, 79% analyst buy ratings, and $87.08 price target upside. Key risks include energy market volatility and high debt levels. The company's strategic acquisitions and AI-driven natural gas demand create growth opportunities, though investors should monitor execution risks and macroeconomic headwinds affecting the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
